Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $891000.0.

  • Century Therapeutics' Share-based Compensation fell 7314.65% to $891000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 3966.89%. This contributed to the annual value of $12.7 million for FY2024, which is 1322.66% down from last year.
  • As of Q3 2025, Century Therapeutics' Share-based Compensation stood at $891000.0, which was down 7314.65% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Share-based Compensation ranged from a high of $4.0 million in Q3 2023 and a low of $891000.0 during Q3 2025
  • Its 4-year average for Share-based Compensation is $2.9 million, with a median of $2.8 million in 2022.
  • As far as peak fluctuations go, Century Therapeutics' Share-based Compensation surged by 5953.78% in 2023, and later crashed by 7314.65% in 2025.
  • Century Therapeutics' Share-based Compensation (Quarter) stood at $2.7 million in 2022, then soared by 30.38% to $3.6 million in 2023, then fell by 25.32% to $2.7 million in 2024, then crashed by 66.5% to $891000.0 in 2025.
  • Its Share-based Compensation stands at $891000.0 for Q3 2025, versus $2.2 million for Q2 2025 and $2.4 million for Q1 2025.